scholarly article | Q13442814 |
P356 | DOI | 10.1038/NRUROL.2011.144 |
P8608 | Fatcat ID | release_3l3n7kw3xvgpreo7ys4p6h3v7m |
P698 | PubMed publication ID | 21989305 |
P2093 | author name string | Medscape | |
Gary D Steinberg | |||
Sandip M Prasad | |||
G Joel Decastro | |||
P2860 | cites work | Cancer statistics, 2010 | Q27860525 |
The cancer genome | Q29547643 | ||
A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment | Q30421675 | ||
Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: analysis of data from the Surveillance, Epidemiology and End Results Program data base | Q30767936 | ||
Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration | Q30991559 | ||
Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration | Q30991564 | ||
Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base | Q33287299 | ||
An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer | Q33438009 | ||
Micropapillary bladder cancer: a review of Léon Bérard Cancer Center experience | Q33469979 | ||
Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma | Q33670824 | ||
Multivariate analysis of the prognostic factors of primary superficial bladder cancer | Q33799104 | ||
Urine cytology. It is still the gold standard for screening? | Q33851115 | ||
Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses | Q34174003 | ||
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer | Q34226107 | ||
Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results | Q34667307 | ||
Effects of individual-level socioeconomic factors on racial disparities in cancer treatment and survival: findings from the National Longitudinal Mortality Study, 1979-2003. | Q34961124 | ||
Use of high-throughput DNA microarrays to identify biomarkers for bladder cancer | Q35036724 | ||
Do mixed histological features affect survival benefit from neoadjuvant platinum‐based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group‐Directed Intergroup Study (S8710) | Q35051123 | ||
Prognostic significance of vascular and perineural invasion in urothelial bladder cancer treated with radical cystectomy | Q35063376 | ||
The value of a second transurethral resection in evaluating patients with bladder tumours | Q35071427 | ||
Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status | Q35187828 | ||
Multi–Detector Row CT Urography in the Evaluation of Hematuria | Q35582739 | ||
Initial tumor stage and grade as a predictive factor for recurrence in patients with stage T1 grade 3 bladder cancer. | Q35604142 | ||
Squamous cell carcinoma of the bladder: pathology, diagnosis and treatment. | Q35613672 | ||
Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis | Q35624838 | ||
Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy. | Q45994760 | ||
Trends in pelvic lymphadenectomy at the time of radical cystectomy: 1988 to 2004. | Q46118519 | ||
Gender and geographic influence on the racial disparity in bladder cancer mortality in the US. | Q46229060 | ||
Hydronephrosis as a prognostic indicator in bladder cancer patients | Q46447197 | ||
A case of relapsing secondary bladder adenocarcinoma after right colonic cancer | Q46499515 | ||
Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer | Q46610841 | ||
Artificial intelligence in predicting bladder cancer outcome: a comparison of neuro-fuzzy modeling and artificial neural networks. | Q47594338 | ||
Conservative management of low risk superficial bladder tumors | Q48548171 | ||
Factors affecting recurrence and progression in superficial bladder tumours. | Q51046351 | ||
Does the presence of muscularis propria on transurethral resection of bladder tumour specimens affect the rate of upstaging in cT1 bladder cancer? | Q51738112 | ||
The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. | Q51819769 | ||
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. | Q51953901 | ||
Neural network analysis of clinicopathological and molecular markers in bladder cancer. | Q52082615 | ||
Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. | Q53263269 | ||
Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. | Q53462584 | ||
Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. | Q53466370 | ||
Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer. | Q53493936 | ||
Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ | Q53591287 | ||
Gender differences in stage distribution of bladder cancer | Q57307308 | ||
Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin as First-Line Chemotherapy in Advanced Transitional Cell Carcinoma of the Urothelium: Results of a Randomized Phase 2 Trial | Q59629290 | ||
Association of Angiogenesis Related Markers With Bladder Cancer Outcomes and Other Molecular Markers | Q59649562 | ||
Can patient selection for bladder preservation be based on response to chemotherapy? | Q61900098 | ||
The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma | Q68180488 | ||
Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study | Q73798367 | ||
Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome | Q74463742 | ||
Evaluation of clinical staging before cystectomy in transitional cell bladder carcinoma: a long-term follow-up of 276 consecutive patients | Q74674542 | ||
The value of a second transurethral resection in evaluating patients with bladder tumors | Q77914322 | ||
Impact of a second transurethral resection on the staging of T1 bladder cancer | Q78508168 | ||
An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma | Q78645466 | ||
Extent of surgery and pathology evaluation has an impact on bladder cancer outcomes after radical cystectomy | Q78860560 | ||
Delaying Radical Cystectomy for Muscle Invasive Bladder Cancer Results in Worse Pathological Stage | Q79075055 | ||
Chemoprevention of bladder cancer | Q79263915 | ||
The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer | Q79805550 | ||
Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer | Q79832999 | ||
Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience | Q79847300 | ||
Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy | Q80395918 | ||
Outcomes in patients with pathological carcinoma in situ only disease at radical cystectomy | Q80450576 | ||
Outcome after radical cystectomy with limited or extended pelvic lymph node dissection | Q80553123 | ||
The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer | Q80615790 | ||
Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder | Q81441276 | ||
Advanced bladder cancer: so many drugs, so little progress : what's wrong with this picture? | Q81614011 | ||
Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder | Q81634328 | ||
Sex and racial differences in bladder cancer presentation and mortality in the US | Q82918430 | ||
The value of a second transurethral resection for T1 bladder cancer | Q82980705 | ||
Sex and race in bladder cancer: what we have learned and future directions | Q83004160 | ||
The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial | Q83116457 | ||
Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort | Q83229154 | ||
Early vs delayed radical cystectomy for 'high-risk' carcinoma not invading bladder muscle: delay of cystectomy reduces cancer-specific survival | Q83229181 | ||
Urothelial carcinoma versus squamous cell carcinoma of bladder: is survival different with stage adjustment? | Q83296498 | ||
Bladder cancer | Q84058686 | ||
The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables | Q84215941 | ||
Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer | Q84415859 | ||
Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? | Q84795217 | ||
Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium | Q93606365 | ||
The health economics of bladder cancer: a comprehensive review of the published literature. | Q35642541 | ||
Gene discovery in bladder cancer progression using cDNA microarrays | Q35791851 | ||
Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. | Q35833326 | ||
Second-line intravesical therapy versus cystectomy for bacille Calmette-Guérin (BCG) failures | Q35858348 | ||
T1G3 bladder cancer--indications for early cystectomy | Q35875210 | ||
Genetic and epigenetic aspects of bladder cancer | Q36067118 | ||
The role of lymphadenectomy in high-grade invasive bladder cancer | Q36111234 | ||
Urothelial tumorigenesis: a tale of divergent pathways | Q36234720 | ||
Non-muscle-invasive bladder cancer: the role of radical cystectomy | Q36312300 | ||
The role of taxanes in the management of bladder cancer | Q36325413 | ||
Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? | Q36341182 | ||
Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers | Q36363225 | ||
Genetic alterations in urothelial bladder carcinoma: an updated review | Q36393012 | ||
Lymphovascular invasion as a prognostic tool for advanced bladder cancer | Q36564692 | ||
Treatment options for BCG failures. | Q36615027 | ||
New imaging modalities in bladder cancer | Q36653218 | ||
Case of carcinosarcoma of urinary bladder obtained a pathologically complete response by neoadjuvant chemoradiotherapy | Q36697819 | ||
Defining optimal therapy for muscle invasive bladder cancer | Q36707709 | ||
Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. | Q36729145 | ||
Intravesical treatments of bladder cancer: review. | Q36738254 | ||
Immunotherapeutic strategies for high-risk bladder cancer | Q36768976 | ||
Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients | Q36836840 | ||
Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. | Q36866916 | ||
Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience | Q36871918 | ||
Novel strategies for treating relapsed/refractory urothelial carcinoma | Q36995686 | ||
Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update | Q36997480 | ||
The Will Rogers phenomenon in urological oncology | Q36998785 | ||
Urinary markers in bladder cancer | Q37046221 | ||
Nomograms for bladder cancer | Q37061242 | ||
The impact of variant histology on the outcome of bladder cancer treated with curative intent | Q37119414 | ||
Molecular biomarkers in urothelial bladder cancer | Q37123497 | ||
Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis. | Q37125906 | ||
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder | Q37158767 | ||
Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. | Q37221832 | ||
Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer | Q37314551 | ||
Small cell carcinoma of the urinary bladder: a 15-year retrospective review of treatment and survival in the Anglian Cancer Network | Q37348345 | ||
Divergent differentiation in urothelial carcinoma and other bladder cancer subtypes with selected mimics | Q37380015 | ||
Polymorphisms in DNA repair genes, smoking, and bladder cancer risk: findings from the international consortium of bladder cancer | Q37434877 | ||
Combination of BCG and interferon intravesical immunotherapy: an update. | Q37500031 | ||
Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications | Q37507542 | ||
Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses | Q37676425 | ||
Are nomograms needed in the management of bladder cancer? | Q37685558 | ||
Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer | Q37787119 | ||
Vinflunine in the treatment of advanced bladder cancer | Q37821892 | ||
Neoadjuvant systemic therapy or early cystectomy? Single-center analysis of outcomes after therapy for patients with clinically localized micropapillary urothelial carcinoma of the bladder | Q37836129 | ||
Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. | Q37859970 | ||
Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma | Q38448798 | ||
Intravesical combination treatment with antisense oligonucleotides targeting heat shock protein-27 and HTI-286 as a novel strategy for high-grade bladder cancer | Q39822041 | ||
Novel intravesical therapies for non-muscle-invasive bladder cancer refractory to BCG. | Q39904370 | ||
Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. | Q40009253 | ||
Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. | Q40348441 | ||
Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study | Q40543930 | ||
A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study | Q40731377 | ||
The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer | Q40751576 | ||
The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index. | Q40854612 | ||
Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. | Q41073539 | ||
Superficial bladder cancer: the primacy of grade in the development of invasive disease | Q41334965 | ||
High-grade hyperinvasive sarcomatoid urothelial bladder carcinoma demonstrating complete response to bladder-preserving chemoradiation | Q41508463 | ||
BCAN Think Tank session 3: Prevention of bladder cancer | Q43075685 | ||
Sequential adjuvant chemotherapy after surgical resection of high-risk urothelial carcinoma | Q43294213 | ||
Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). | Q43450732 | ||
Predicting recurrence and progression in non-muscle-invasive bladder cancer using European organization of research and treatment of cancer risk tables. | Q44057900 | ||
Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases | Q44271939 | ||
Selenium and bladder cancer risk: a meta-analysis. | Q44325332 | ||
Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer | Q44689045 | ||
Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study | Q44870028 | ||
A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials | Q44883456 | ||
Small cell carcinoma of the urinary bladder. The Mayo Clinic experience | Q45077919 | ||
Effective therapy for metastatic renal cancer, whither to now. | Q45219473 | ||
Pathological upstaging during radical cystectomy is associated with worse recurrence-free survival in patients with bacillus Calmette-Guerin-refractory bladder cancer | Q45340458 | ||
Bladder cancer: analysis of multi-detector row helical CT enhancement pattern and accuracy in tumor detection and perivesical staging. | Q45907687 | ||
Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. | Q45967681 | ||
FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. | Q45992013 | ||
P433 | issue | 11 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 631-642 | |
P577 | publication date | 2011-10-11 | |
P1433 | published in | Nature Reviews Urology | Q2079265 |
P1476 | title | Urothelial carcinoma of the bladder: definition, treatment and future efforts | |
P478 | volume | 8 |
Q38721568 | ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer |
Q36739002 | ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer. |
Q38131409 | Alterations of DNA methylome in human bladder cancer. |
Q97519531 | BORA regulates cell proliferation and migration in bladder cancer |
Q42465565 | Bladder cancers arise from distinct urothelial sub-populations. |
Q36272100 | CLASP2 is involved in the EMT and early progression after transurethral resection of the bladder tumor |
Q36490303 | CMTM8 inhibits the carcinogenesis and progression of bladder cancer |
Q38686052 | Cantharidin alters the expression of genes associated with the NKG2D-associated immune response in TSGH-8301 human bladder carcinoma cells |
Q92744195 | Celecoxib inhibits the epithelial-to-mesenchymal transition in bladder cancer via the miRNA-145/TGFBR2/Smad3 axis |
Q91842173 | CircPTPRA acts as a tumor suppressor in bladder cancer by sponging miR-636 and upregulating KLF9 |
Q47694209 | Clinical Proteomics for Precision Medicine: The Bladder Cancer Case |
Q39404314 | Cyclin-dependent kinase 4 is a novel target in micoRNA-195-mediated cell cycle arrest in bladder cancer cells |
Q54090828 | Detection of urothelial carcinoma, upper tract urothelial carcinoma, bladder carcinoma, and urothelial carcinoma with gross hematuria using selected urine-DNA methylation biomarkers: A prospective, single-center study. |
Q39318239 | Do histological variants in urothelial carcinoma of the bladder portend poor prognosis? A systematic review and meta-analysis |
Q51062025 | Downregulated KLK13 expression in bladder cancer highlights tumor aggressiveness and unfavorable patients' prognosis. |
Q35956711 | Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study |
Q47170529 | Expression of ganglioside GD2, reprogram the lipid metabolism and EMT phenotype in bladder cancer |
Q28074732 | Genetic and Epigenetic Alterations in Bladder Cancer |
Q46779353 | Inflammatory microenvironment in the initiation and progression of bladder cancer |
Q41339763 | Insights from animal models of bladder cancer: recent advances, challenges, and opportunities |
Q91670697 | Kinesin family member C1 accelerates bladder cancer cell proliferation and induces epithelial-mesenchymal transition via Akt/GSK3β signaling |
Q34717627 | Knockdown of regulator of cullins-1 (ROC1) expression induces bladder cancer cell cycle arrest at the G2 phase and senescence |
Q35022673 | Lack of decorin expression by human bladder cancer cells offers new tools in the therapy of urothelial malignancies |
Q58093528 | Loss of GAS5 tumour suppressor lncRNA: an independent molecular cancer biomarker for short-term relapse and progression in bladder cancer patients |
Q38715315 | Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2. |
Q37317523 | Metformin represses bladder cancer progression by inhibiting stem cell repopulation via COX2/PGE2/STAT3 axis |
Q36557362 | Methylomics analysis identifies ZNF671 as an epigenetically repressed novel tumor suppressor and a potential non-invasive biomarker for the detection of urothelial carcinoma. |
Q90478682 | MiR-362-5p, Which Is Regulated by Long Non-Coding RNA MBNL1-AS1, Promotes the Cell Proliferation and Tumor Growth of Bladder Cancer by Targeting QKI |
Q35605883 | MicroRNA-320c inhibits tumorous behaviors of bladder cancer by targeting Cyclin-dependent kinase 6 |
Q33642335 | MicroRNAs as biomarkers associated with bladder cancer |
Q35285703 | Modelling bladder cancer in mice: opportunities and challenges |
Q26825948 | Normal and neoplastic urothelial stem cells: getting to the root of the problem |
Q41486372 | Overexpression of HMGB3 protein promotes cell proliferation, migration and is associated with poor prognosis in urinary bladder cancer patients |
Q36574137 | Overexpression of RNF2 Is an Independent Predictor of Outcome in Patients with Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy |
Q44581657 | PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors |
Q64055449 | PPARγ inhibition regulates the cell cycle, proliferation and motility of bladder cancer cells |
Q100515374 | Part 1. Evaluation of epigallocatechin gallate or tannic acid formulations of hydrophobic drugs for enhanced dermal and bladder uptake or for local anesthesia effects |
Q89761556 | Patient-Derived Xenograft Models in Urological Malignancies: Urothelial Cell Carcinoma and Renal Cell Carcinoma |
Q38714374 | Patient-derived xenografts as in vivo models for research in urological malignancies |
Q47727562 | Prognostic Power of a Tumor Differentiation Gene Signature for Bladder Urothelial Carcinomas |
Q27324419 | Protein Profiling of Bladder Urothelial Cell Carcinoma |
Q42378347 | Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention |
Q39038597 | Quantitative proteomics of fractionated membrane and lumen exosome proteins from isogenic metastatic and nonmetastatic bladder cancer cells reveal differential expression of EMT factors |
Q33919252 | Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014). |
Q49168184 | Significant expression of CHK1 and p53 in bladder urothelial carcinoma as potential therapeutic targets and prognosis |
Q37256055 | TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism |
Q47670544 | The Stromal Niche for Epithelial Stem Cells: A Template for Regeneration and a Brake on Malignancy |
Q36339910 | The prognostic significance of DAPK1 in bladder cancer |
Q53119894 | Tissue Permeability Effects Associated with the Use of Mucoadhesive Cationic Nanoformulations of Docetaxel in the Bladder. |
Q52602391 | Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer. |
Q43717784 | Uncovering the clinical utility of miR-143, miR-145 and miR-224 for predicting the survival of bladder cancer patients following treatment |
Q35056092 | Upregulated WDR5 promotes proliferation, self-renewal and chemoresistance in bladder cancer via mediating H3K4 trimethylation |
Q39097235 | Urothelial generation and regeneration in development, injury, and cancer. |
Q48225163 | miR-221/222 cluster expression improves clinical stratification of non-muscle invasive bladder cancer (TaT1) patients' risk for short-term relapse and progression |
Q90600278 | ΔNp63 transcript loss in bladder cancer constitutes an independent molecular predictor of TaT1 patients post-treatment relapse and progression |
Search more.